在心脏瘤学中,可溶性 neprilysin 和转化连续体
Massimiliano Camilli1,2, Antonio Abbate3
1Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy. massimiliano.camilli91@gmail.com.
Cardio-oncology (London, England)
|January 8, 2026
概括
ангиотензин受体/内普利辛抑制剂 (ARNI) 在心力衰竭方面表现有前途,但在癌症患者中尚未出现. 溶性 neprilysin (sNEP) 可能预测ARNI在化疗引起的心脏损伤中的益处,这表明精确医学方法.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 药理学 药理学是指药理学的学科.
- 生物标志物 生物标志物
背景情况:
- 心脏瘤学在将机械学发现转化为临床心脏保护方面面临着挑战.
- ангиотензин受体/内普利辛抑制剂 (ARNI) 有益于心力衰竭,但缺乏在心脏瘤学中的有效性.
- 将临床前见解与患者护理联系在一起仍然是一个重大障碍.
研究的目的:
- 调查溶性 neprilysin (sNEP) 作为预测性生物标志物的作用,以确定 ARNI 在人环素诱导心脏毒性的有效性.
- 在由生物标志物指导的心脏瘤学中探索精准医学策略.
主要方法:
- 采用了一种临床前模型,分析了由环素诱导的心脏毒性.
- 监测可溶性 neprilysin (sNEP) 的水平.
- 评估心肌损伤和缩功能障碍.
主要成果:
- 溶性 neprilysin (sNEP) 水平与炭环素诱导的心肌损伤和功能障碍相关.
- 在这个临床前模型中,sNEP水平显示出作为ARNI益处预测者的潜力.
结论:
- 像sNEP这样的生物标志物可以识别出可以从心脏瘤学中ARNI治疗中受益的患者.
- 使用生物标志物的精准医学方法对于推进癌症患者的心脏保护策略至关重要.
- 需要进一步的临床试验来验证sNEP作为ARNI治疗选择的生物标志物.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:24Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
01:16Clot Retraction and Fibrinolysis
8.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915